Insights

Latest thinking from our team

Expert perspectives on real-world evidence, health economics, and AI in life sciences.

August 2026

From Regulatory Milestone to Market Access: Building an Evidence Continuum That Decision-Makers Can Use

Regulatory milestones are only the start. Learn how connected SLR, NMA, HEOR, RWE and economic modelling can strengthen market-access evidence. A regulatory mil...

August 2026

Evidence Before the Milestone: Building HTA, RWE and Economic Strategy for Advanced Therapies

Why advanced therapies need early, integrated planning for evidence synthesis, external controls, RWE, economic modelling, HTA and reimbursement? A pivotal-tria...

August 2026

The Evidence Clock Starts Before the Pivotal Readout

Recent life-sciences signals reveal a consistent pattern across oncology, immunology, rare disease, medical devices and digital health. Positive pivotal results...

July 2026

Revagenix’s Rev-56 Enters Phase 1: Why Bronchiectasis Evidence Strategy Must Start Before Efficacy Data

Revagenix’s Rev-56 Enters Phase 1: Why Bronchiectasis Evidence Strategy Must Start Before Efficacy Data Revagenix announced on 27 July 2026 that the first...